期刊文献+
共找到180篇文章
< 1 2 9 >
每页显示 20 50 100
The study of engraft evidence in allogeneic bone marrow transplantation by 9 short tandem repeats loci
1
《中国输血杂志》 CAS CSCD 2001年第S1期376-,共1页
关键词 bone The study of engraft evidence in allogeneic bone marrow transplantation by 9 short tandem repeats loci
下载PDF
Attenuation of GVHD for Allo-Bone Marrow Transplantation Recipient by FasL-Fas Pathway in an H-2 Haplotype Disparate Mouse Combination
2
作者 刘凌波 邹萍 +4 位作者 胡中波 仲照东 肖娟 郭荣 徐之良 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第4期329-333,共5页
In order to explore a new special and effective way to prevent graft versus host disease (GVHD) after allogenic bone marrow transplantation (allo-BMT), the stem cell antigen-1 (Sca-1) + early hematopoietic cells (EHC... In order to explore a new special and effective way to prevent graft versus host disease (GVHD) after allogenic bone marrow transplantation (allo-BMT), the stem cell antigen-1 (Sca-1) + early hematopoietic cells (EHC) from BALB/c mouse (H-2 d) were introduced with exogenous mouse Fas ligand (mFasL) cDNA gene by the retrovirus-mediated gene transfer and expanded for one week, and then they were co-cultured with the spleen mononuclear cells (SMNC) from BAC mouse (H-2 d×b) as one way mixed lymphocyte reaction (OWMLR). The cytotoxicity of treated BAC mouse SMNC against Na 2 51CrO 4 labeling SMNC from BALB/c mouse was observed. The bone marrow mononuclear cells (BMMNC) from BAC mouse treated by the above methods were transplanted into lethally-irradiated congenic BALB/c mice to observe the occurrence of GVHD. The results showed that the SMNC from BAC mouse after OWMLR with exogenous mFasL cDNA gene-transduced hematopoietic cells (HC) from BALB/c mouse in a ratio of 1 to 5 exhibited an obvious inhibition of the cytotoxicity against the BALB/c mouse spleen cells at different effector/target ratios as compared to the control group (P<0.01). The gradeⅠ GVHD or no GVHD and the 80 % survival rate at day 60 post-BMT were observed in the BALB/c mouse receiving BAC mouse BMMNC treated with similar way, while the grade Ⅱ-Ⅲ GVHD and the 20 % survival rate were noted in the control group (P<0.01). It is suggested that the attenuation of GVHD in allo-BMT recipient could be successfully achieved through FasL-Fas pathway in an H-2 haplotype disparate mouse combination. 展开更多
关键词 Fas ligand Fas allogenic bone marrow transplantation graft versus host disease
下载PDF
After allogenic bone marrow transplantation agent of hemorrhagic cystitis: BK virus
3
作者 Berber Ilhami Koroglu Mustafa +5 位作者 Erkurt Mehmet Ali Oguz Fatih Altintas Ramazan Kaya Emin Kuku Irfan Ulutas Ozkan 《Case Reports in Clinical Medicine》 2013年第5期298-301,共4页
Hemorrhagic cystitis is a common and in its severe form potentially life threatening complication of hematopoietic stem cell transplantation. Hemorrhagic cystitis is defined as a diffuse inflammatory condition of the ... Hemorrhagic cystitis is a common and in its severe form potentially life threatening complication of hematopoietic stem cell transplantation. Hemorrhagic cystitis is defined as a diffuse inflammatory condition of the urinary bladder due to an infectious or noninfectious etiology resulting in bleeding from the bladder mucosa. Hemorrhagic cystitis is characterized by lower urinary tract symptoms including dysuria, hematuria and hemorrhage. The most common cause is a bacterial infection that usually responds promptly to treatment. But chronic and recurrent hemorrhagic cystitis often arises from anticancer chemotherapy or radiotherapy for the treatment of pelvic malignancies. Infectious etiologies are less common causes of chronic hemorrhagic cystitis except in immunocompromised hosts like bone marrow transplant recipients. Hemorrhagic cystitis is a significant complication of bone marrow transplantation which influences economic and survival outcome. Hemorrhagic cystitis can be divided into two classes according to onset time;early and late onset time. Earlyonset hemorrhagic cystitis is commonly associated used with chemo-radiotherapy protocols in some of the preparatory regimens. More than one factor is accused in the etiology of late onset hemorrhagic cystitis. Here, we present a patient whose hematuria started after 54 days from allogeneic stem cell transplantation. 展开更多
关键词 alloGENIC bone marrow transplantation
下载PDF
THE STRATEGIES FOR PREVENTING AND TREATING IN-FECTION OF CYTOMEGALOVIRUS IN BONE MARROW TRANSPLANTATION
4
作者 张梅 刘陕西 +2 位作者 王宝燕 刘心 蔡瑞波 《Journal of Pharmaceutical Analysis》 CAS 1999年第1期46-48,93,共4页
In bone marrow transplantation (BMT), cytomegalovirus (CMV) interstitial pneumonitis (IP) is one of the most dangerous complications, which has been the first important cause to lead the failure of BMT. At present, t... In bone marrow transplantation (BMT), cytomegalovirus (CMV) interstitial pneumonitis (IP) is one of the most dangerous complications, which has been the first important cause to lead the failure of BMT. At present, there is no effective and specific therapy for CMVIP, therefore how to prevent CMV infection effectively is a top task. From 1991 to 1996, we used comprehensive steps to prevent CMVIP in BMT, and none of 14 patients developed CMVIP. The preventing results that we achieved by using the steps were quite satisfied. 展开更多
关键词 bone marrow transplantation (bmt) prevention cytomegalovirus (CMV) interstitial pneumonitis(IP)
下载PDF
Cost Effectiveness Analysis of Filgrastim versus Placebo in Post AIIogentic Bone Marrow Transplantation
5
作者 Maoudoud Ines Razgallah Khrouf Myriam +8 位作者 Ben Abdejelil Nour Ghedira Hela Amel Lakhal Marsit Hanene Turki Manel Soussi Mohamed Ali Lazreg Olfa Ladab Saloua Ben Othmane Tarek 《Journal of Pharmacy and Pharmacology》 2016年第6期268-272,共5页
Filgrastim is used to accelerate hematopoietic recovery after ABMT (allogeneic bone marrow transplantation). Its impact on the total cost of patient care remains to be explored. We therefore undertook a cost effecti... Filgrastim is used to accelerate hematopoietic recovery after ABMT (allogeneic bone marrow transplantation). Its impact on the total cost of patient care remains to be explored. We therefore undertook a cost effectiveness analysis in the context of a randomized single blinded clinical trial of Filgrastim versus placebo in post ABMT. A primary endpoint, duration of myelosuppression, and three secondary end points (number of days of fever, length of hospital stay, survival at one hundred days) were used to assess efficacy. Direct costs were evaluated and allowed the calculation of the ICER (incremental cost-effectiveness ratios) for the major endpoint of the trial. Sixteen patients were included in the study. The duration of myelosuppression was significantly decreased in the Filgrastim arm with medians of 15 days vs. 19 days in the placebo arm (p = 0.023). Cost analysis showed no statistically significant difference between the two arms. According to the calculation of ICER, Filgrastim was more costly and more effective than placebo for the number of days of aplasia avoided and the number of days with fever avoided. Placebo strictly dominated filgrastim for days of hospitalization avoided. Filgrastim has proven effective in reducing the duration of aplasia without increasing costs. 展开更多
关键词 FILGRASTIM PLACEBO COST EFFECTIVENESS allogeneic bone marrow transplantation.
下载PDF
An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation 被引量:17
6
作者 黄晓军 郭乃榄 +3 位作者 任汉云 张耀臣 高志勇 陆道培 《Chinese Medical Journal》 SCIE CAS CSCD 2003年第5期736-741,共6页
Objective To observe the antileukemic effect in relapse patients by infusion of donor immunocompetent cells with or without granulocyte colony-stimulating factor (G-CSF) mobilization.Methods Twenty patients with leu... Objective To observe the antileukemic effect in relapse patients by infusion of donor immunocompetent cells with or without granulocyte colony-stimulating factor (G-CSF) mobilization.Methods Twenty patients with leukemia in relapse after allogeneic bone marrow transplantation (allo-BMT) were treated with chemotherapy followed by donor-derived lymphocytes (DDL) without G-CSF mobilization (Group A, n=11), or donor peripheral blood progenitor cells (PBPCs) with G-CSF mobilization (Group B, n=9).Results Five patients in Group A were in hematologic relapse. After DDL infusion, 3 of 5 patients had a temporary complete remission (CR) and relapsed after 3, 7 and 10 months, respectively. One achieved partial remission and died of interstitial pneumonia; and the other one showed no response. Another 6 patients in Group A were in cytogenetic relapse or central nerve system (CNS) leukemia, and all achieved CR and remained in disease free survival (DFS) for 10 to 98 months after DDL infusion. All 9 patients in group B were in hematologic relapse. Three patients with chronic myeloid leukemia (CML) had cytogenetic and molecular remission for 16, 35 and 51 months, respectively after PBPC infusion; and 5 patients with acute lymphoid leukemia (ALL) had CR and were still in CR for 10 to 18 months except 1 patient relapsed soon. And the other one with AML showed no response to the therapy.Conclusion Donor immunocompetent cells infusion is an effective therapy for relapsed leukemia after allo-BMT, especially for the patients with early (molecular and cytogenetic) or CNS relapse. Infusion of donor PBPC mobilized by G-CSF seems to have more potentiated graft-versus-leukemia (GVL) effect than DDL infusion. 展开更多
关键词 donor-derived lymphocyte · donor peripheral blood progenitor cell · allogeneic bone marrow transplantation · RELAPSE
原文传递
Relapse of acute lymphoblastic leukemia in the pancreas after allogeneic bone marrow transplantation 被引量:2
7
作者 ZHAO Xiao-mu ZHANG Zhong-tao LI Jian-she HAN Wei 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第22期3364-3366,共3页
The occurrence of metastatic lesions in the pancreas of patients with cancer, including hematological cancers,is uncommon (1.6%-37.5%) and of these, the majority of patients will have widespread disease.1-7 Isolated... The occurrence of metastatic lesions in the pancreas of patients with cancer, including hematological cancers,is uncommon (1.6%-37.5%) and of these, the majority of patients will have widespread disease.1-7 Isolated potentially resectable pancreatic metastases are rarely seen. Resection of metastatic tumors of the pancreas has been reported, but its role in improving survival rates or quality of life is not clear.7,8 However, 展开更多
关键词 PANCREAS acute leukemia RELAPSE allogeneic bone marrow transplantation
原文传递
Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation
8
作者 Feifei Tang Xiaodong Mo +13 位作者 Xiaohui Zhang Yu Wang Chenhua Yan Yuhong Chen Huan Chen Wei Han Yao Chen Fengrong Wang Jingzhi Wang Yuqian Sun Yuanyuan Zhang Kaiyan Liu Xiaojun Huang Lanping Xu 《Science China(Life Sciences)》 SCIE CAS CSCD 2020年第1期138-147,共10页
This study evaluated the influence of the degree of donor bone marrow(BM)hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Twelve patients received allo-HSCT ... This study evaluated the influence of the degree of donor bone marrow(BM)hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Twelve patients received allo-HSCT from hypoplastic BM donors between January 2010 and December 2017.Forty-eight patients whose donors demonstrated BM hyperplasia were selected using a propensity score matching method(1:4).Primary graft failure including poor graft function and graft rejection did not occur in two groups.In BM hypoplasia and hyperplasia groups,the cumulative incidence(CI)of neutrophil engraftment at day 28(91.7%vs.93.8%,P=0.75),platelet engraftment at day 150(83.3%vs.93.8%,P=0.48),the median time to myeloid engraftment(14 days vs.14 days,P=0.85)and platelet engraftment(14 days vs.14 days,P=0.85)were comparable.The 3-year progression-free survival,overall survival,CI of non-relapse mortality and relapse were 67.8%vs.71.7%(P=0.98),69.8%vs.77.8%(P=0.69),18.5%vs.13.6%(P=0.66),and 10.2%vs.10.4%(P=0.82),respectively.In multivariate analysis,donor BM hypoplasia did not affect patient clinical outcomes after allo-HSCT.If patients have no other suitable donor,a donor with BM hypoplasia can be used for patients receiving allo-HSCT if the donor Complete Blood Count and other examinations are normal. 展开更多
关键词 bone marrow aspirate HYPOPLASIA hyperplasic normal donor allogeneic hematopoietic stem cell transplantation
原文传递
FILGRASTIM (G-CSF) FOR ALLOGENEIC BONE MARROW TRANSPLANTATION
9
作者 T.Masaoka 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第10期21-22,共2页
Conditioning for allogeneic bone marrow transplantation causes severe neutropenia until new
关键词 G-CSF FILGRASTIM FOR allogeneic bone marrow transplantation
原文传递
TREATMENT OF APLASTIC ANEMIA: ALLOGENEIC BONE MARROW TRANSPLANTATION VERSUS IMMUNOMODULATION THERAPY WITH ANTILYMPHOCYTE GLOBULIN
10
作者 CCKim JYJin DjKim 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第10期17-18,共2页
There are two arms in the management of aplastic anemia,one allogeneic bone marrow transplantation(BMT) and the other immunomodulation therapy with antilymphocyte globulin(ALG).
关键词 OVER TREATMENT OF APLASTIC ANEMIA CR allogeneic bone marrow transplantation VERSUS IMMUNOMODULATION THERAPY WITH ANTILYMPHOCYTE GLOBULIN
原文传递
THE ROLE OF ETOPOSIDE (VP-16) IN PREPARATORY REGIMENS FOR PATIENTS WITH LEUKEMIA UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION
11
作者 S.Issaragrisil 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第10期16-17,共2页
In 1983,we began a series of five clinical trials with the goal of reducing the relapse rate following
关键词 VP-16 IN PREPARATORY REGIMENS FOR PATIENTS WITH LEUKEMIA UNDERGOING allogeneic bone marrow transplantation THE ROLE OF ETOPOSIDE
原文传递
小剂量骨髓联合外周血造血干细胞移植治疗重型再生障碍性贫血18例临床研究
12
作者 彭文 唐娜娜 +6 位作者 王倩 肖青 唐晓琼 张红宾 王利 刘林 罗小华 《内科急危重症杂志》 2024年第3期229-234,269,共7页
目的:探讨小剂量骨髓联合外周血造血干细胞(PBSC)移植治疗重型再生障碍性贫血(SAA)的疗效及安全性。方法:纳入以小剂量骨髓(中位体积200 mL)联合PBSC移植治疗的18例SAA患者的临床资料,回顾分析其造血重建情况、移植物抗宿主病(GVHD)发... 目的:探讨小剂量骨髓联合外周血造血干细胞(PBSC)移植治疗重型再生障碍性贫血(SAA)的疗效及安全性。方法:纳入以小剂量骨髓(中位体积200 mL)联合PBSC移植治疗的18例SAA患者的临床资料,回顾分析其造血重建情况、移植物抗宿主病(GVHD)发生率、感染发生率及生存率等指标。结果:18例患者的中位年龄27(13~52)岁,男11例,女7例;SAA-Ⅰ型15例,SAA-Ⅱ型3例;单倍体相合供者15例,同胞全相合供者3例;预处理:氟达拉滨+环磷酰胺+抗人胸腺球蛋白方案2例,氟达拉滨+环磷酰胺+移植后环磷酰胺方案8例,氟达拉滨+环磷酰胺+抗人胸腺球蛋白+移植后环磷酰胺方案8例;采用环孢素或他克莫司+短疗程甲氨蝶呤联合吗替麦考酚酯预防GVHD。所有患者均获得造血重建,仅1例患者出现继发性移植物功能不良;10例(55.6%)出现总计19例次移植后感染,其中10例次为巨细胞病毒(CMV)或EB病毒(EBV)血症,6例次细菌感染;急性GVHD发生率为16.7%,其中Ⅰ度1例,Ⅱ度2例;慢性GVHD发生率为16.7%,均为轻度;中位随访26(2~64)个月,移植后2年总生存率为72.2%(95%CI:51.4~93.0)。5例患者死亡,4例死于肺部感染,1例死于颅内感染。结论:采用小剂量骨髓联合PBSC是SAA患者进行造血干细胞移植的有效且可行的移植物选择策略。 展开更多
关键词 小剂量骨髓 外周造血干细胞 异基因造血干细胞移植 重型再生障碍性贫血
下载PDF
Bone marrow stromal cell line co-transfected with IL-2 and IL-3 genes can accelerate restoration of T-cell immunity in allo-BMT mice 被引量:3
13
作者 李爱玲 蒋激扬 +4 位作者 马建波 王光明 郝洁 高翔 谢蜀生 《Chinese Medical Journal》 SCIE CAS CSCD 2004年第8期1223-1227,共5页
Background After T-cell depleted allogeneic bone marrow transplantation, impaired immune reconstitution is a major cause of morbidity and mortality in the recipient The purpose of this study was to observe the effe... Background After T-cell depleted allogeneic bone marrow transplantation, impaired immune reconstitution is a major cause of morbidity and mortality in the recipient The purpose of this study was to observe the effects of the gene-engineered bone marrow stromal cell line QXMSC1-IL-2+IL-3 on the reconstitution of T-cell immunity in allo-BMT mice Methods The bone marrow stromal cell line QXMSC1 was co-transfected with IL-2 and IL-3 genes using a Tet-on gene expression system T lymphocyte subset counts per spleen were analyzed by flow cytometry Lymphocyte proliferation response to ConA was examined to evaluate T-cell function CDR3 spectratyping techniques were performed to evaluate TCR repertoire diversity at various time points post-transplantation Results Gene engineered bone marrow stromal cell line QXMSC1-IL-2+IL-3 could express IL-2 and IL-3 (1300 ng·day -1 ·10 -6 cells and 1100 ng·day -1 ·10 -6 cells, respectively) under the control of doxycycline QXMSC1-IL-2+IL-3 in combination with allogeneic bone marrow could significantly increase the counts of CD4 + and CD8 + T cell, 1.72 and 1.27-fold respectively at week 3 compared with TCD-BMT group ( P <0.01); make CD4 +/CD8 + ratio return to normal level at week 4; enhance splenocytes mitotic response to ConA ( P <0.01), and accelerate restoration of TCR repertoire diversity in the lethally irradiated mice ( P <0.05) KH*2/5DConclusion The gene transduced stromal cell line QXMSC1-IL-2+IL-3 is able to accelerate T-cell immunity in allo-BMT mice 展开更多
关键词 allogeneic bone marrow transplantation · immune reconstitution · TCR repertoir
原文传递
异基因造血干细胞移植治疗Shwachman-Diamond综合征4例并文献复习
14
作者 陈姣 樊世芬 +2 位作者 刘周阳 姜帆 孙媛 《中国小儿血液与肿瘤杂志》 CAS 2023年第6期351-355,共5页
目的总结Shwachman-Diamond综合征(SDS)临床特点,探讨异基因造血干细胞移植(allo-HSCT)治疗SDS的安全性及有效性。方法回顾性分析2015年7月—2022年2月在北京京都儿童医院治疗的SDS患儿临床资料,并复习相关文献。结果共纳入4例患儿,男2... 目的总结Shwachman-Diamond综合征(SDS)临床特点,探讨异基因造血干细胞移植(allo-HSCT)治疗SDS的安全性及有效性。方法回顾性分析2015年7月—2022年2月在北京京都儿童医院治疗的SDS患儿临床资料,并复习相关文献。结果共纳入4例患儿,男2例,女2例。4例均生后1月以腹泻起病,中位诊断年龄38.5(14-70)个月,均为SBDS基因复合杂合突变。4例均有脂肪泻、淀粉酶减低、胰腺超声或影像学异常、牙齿发育不良及生长发育迟缓。1例严重慢性中性粒细胞减少症,1例急性髓系白血病,2例骨髓增生异常综合征(MDS)。中位移植时间为44.5(25-73)个月。1例行非血缘外周血干细胞移植;3例行非血缘脐带血移植。4例均进行清髓预处理,并成功植入,1例移植后出现MDS复发行二次移植后再次复发。移植后中位随访时间35(14~92)个月,3例无病存活,1例带病存活。结论SDS出现严重血细胞减少、MDS及白血病时,allo-HSCT是安全有效的一种治疗方式。 展开更多
关键词 Shwachman-Diamond综合征 异基因造血干细胞移植 骨髓增生异常综合征 骨髓衰竭 白血病
下载PDF
大鼠骨髓间充质干细胞对同种异体骨髓移植造血重建的影响 被引量:11
15
作者 雷俊霞 朱美玲 +7 位作者 郭振宇 赵东长 余伟华 温冠媚 张秀明 李艳 项鹏 李树浓 《中国实验血液学杂志》 CAS CSCD 2005年第3期397-403,共7页
为了探讨大鼠骨髓间充质干细胞(mesenchymalstemcell,MSC)对同种异体骨髓移植造血重建的影响,建立大鼠同种异体骨髓移植模型,通过外周血像检测、病理分析和流式细胞术检测综合评价MSC对骨髓移植(bonemarrowtransplantation,BMT)的积极... 为了探讨大鼠骨髓间充质干细胞(mesenchymalstemcell,MSC)对同种异体骨髓移植造血重建的影响,建立大鼠同种异体骨髓移植模型,通过外周血像检测、病理分析和流式细胞术检测综合评价MSC对骨髓移植(bonemarrowtransplantation,BMT)的积极作用。结果表明:①共移植后30天,MSC可在致死量照射的受者存活,并被发现受者胸腺、脾脏和骨髓;②MSC可促进BMT后造血重建,促进外周血白细胞、淋巴细胞和血小板的明显恢复;促进骨髓细胞数恢复及B淋巴系、巨核系分化增强;有利骨髓组织学的明显恢复发善。结论:大鼠MSC与骨髓共移植可在受体的造血器官长期存在,MSC可明显促进同种异体骨髓移植后造血重建。 展开更多
关键词 骨髓 间质干细胞 同种异体骨髓移植 造血重建 GVHD
下载PDF
非清髓性骨髓移植诱导异基因受者小鼠免疫耐受的实验研究 被引量:7
16
作者 陈宝安 毕延智 +9 位作者 丁家华 张琰 高冲 孙耘玉 赵钢 王骏 程坚 孙雪梅 Michael Schmitt Hartmut Dhner 《中国实验血液学杂志》 CAS CSCD 2005年第6期1054-1057,共4页
本研究通过非清髓性预处理方案联合髓腔内骨髓移植(IBMBMT)建立异基因小鼠免疫耐受模型,并探讨其诱导耐受的机理。受鼠为雌性C57BL/6(H2b,B6)小鼠,于第0天接受60Coγ线全身照射(TBI),4小时内输注雄性BALB/c(H2d)小鼠来源的骨髓细胞(BMC... 本研究通过非清髓性预处理方案联合髓腔内骨髓移植(IBMBMT)建立异基因小鼠免疫耐受模型,并探讨其诱导耐受的机理。受鼠为雌性C57BL/6(H2b,B6)小鼠,于第0天接受60Coγ线全身照射(TBI),4小时内输注雄性BALB/c(H2d)小鼠来源的骨髓细胞(BMC),2天后腹腔注射环磷酰胺(CTX)。通过皮肤移植、混合淋巴细胞反应(MLR)检测耐受状态,并通过体外过继转移实验、IL2逆转实验等探讨免疫耐受的机制。结果显示,经骨髓移植的B6小鼠对BALB/c小鼠的皮肤移植物平均存活时间(MST)>150天,较对照组明显延长(P<0.01);骨髓移植后第90天,受鼠(黑色)表型开始呈现供鼠(白色)颜色特征。MLR结果证明,B6小鼠获得供体特异性耐受,该耐受可以被IL2逆转且可被过继转移;所有受鼠均未出现GVHD表现。结论:非清髓预处理联合髓腔内骨髓移植可以有效地诱导异基因小鼠免疫耐受,克隆无能、抑制细胞存在及嵌合体产生均参与耐受的形成。 展开更多
关键词 骨髓移植 非清髓性骨髓移植 髓腔内骨髓移植 免疫耐受 皮肤移植
下载PDF
骨髓间质干细胞降低大鼠移植物抗宿主反应的实验研究 被引量:36
17
作者 田莹 邓宇斌 +2 位作者 王亚柱 王晔 朱文标 《免疫学杂志》 CAS CSCD 北大核心 2008年第1期29-33,共5页
目的探讨MSCs对GVHD的作用及其机制。方法建立大鼠同种异体骨髓移植模型,同时输入供者的T淋巴细胞诱导出移植物抗宿主反应,联合或不联合移植供体来源的MSCs,观察受鼠的生存时间,同时利用RT-PCR法研究Th1/Th2淋巴细胞亚群的比例,用ELISA... 目的探讨MSCs对GVHD的作用及其机制。方法建立大鼠同种异体骨髓移植模型,同时输入供者的T淋巴细胞诱导出移植物抗宿主反应,联合或不联合移植供体来源的MSCs,观察受鼠的生存时间,同时利用RT-PCR法研究Th1/Th2淋巴细胞亚群的比例,用ELISA法检测移植后体内IL-4细胞因子的浓度。结果GVHD组的平均生存时间为(17.30±2.33)天,实验组的平均生存时间为(24.10±2.36)天,与单独移植HSCs相比,MSCs与HSCs共移植明显延长的受鼠的生存时间。同时,GVHD组Th1/Th2细胞比值为1.29±0.06,IL-4因子的浓度平均为(14.84±2.59)pg/mL,实验组Th1/Th2细胞比值为(0.77±0.14),IL-4因子的浓度平均为(40.09±13.99)pg/mL。MSCs与HSCs共移植降低了体内Th1/Th2淋巴细胞亚群的比例,提高了体内IL-4细胞因子的浓度。结论MSCs与HSCs共移植能有效抑制HSCs移植后致死性GVHD的发生,延长生存时间,同时MSCs可能通过作用于体内Th1/Th2淋巴细胞亚群的比例,促进体内IL-4细胞因子的分泌从而间接发挥了抑制GVHD的作用。 展开更多
关键词 骨髓间质干细胞 造血干细胞移植 同种异体移植 移植物抗宿主病
下载PDF
G-CSF动员的异基因外周血干细胞和骨髓联合移植治疗白血病 被引量:7
18
作者 鹿全意 牛小青 +4 位作者 郭勇 张鹏 曾晓新 付肖凡 周娟娟 《中国实验血液学杂志》 CAS CSCD 2005年第2期326-328,共3页
为了探讨粒细胞集落刺激因子(G-CSF)动员的异基因外周血干细胞和骨髓联合移植治疗白血病的疗效, 给予供者G-CSF 8-10μg/(kg·d),皮下连续注射5天,以动员外周血和骨髓干细胞,在第4,5天采集外周血干细 胞,第7天采集骨髓;预处理采用... 为了探讨粒细胞集落刺激因子(G-CSF)动员的异基因外周血干细胞和骨髓联合移植治疗白血病的疗效, 给予供者G-CSF 8-10μg/(kg·d),皮下连续注射5天,以动员外周血和骨髓干细胞,在第4,5天采集外周血干细 胞,第7天采集骨髓;预处理采用氟达拉宾,白消安和环磷酰胺组成的新方案。结果表明,12例全部成功植入,中性 粒细胞>0.5×109/L的时间为10.2(9-12)天,血小板>20×109/L的时间为12.5(12-14)天。移植后观察100 天,4例(33.3%)发生Ⅱ度急性移植物抗宿主病(aGVHD),10例出现慢性移植物抗宿主病(cGVHD),中位随访时 间5个月,2例死亡,余10健康生存。结论:G-CSF动员的和外周血造血干细胞骨髓联合移植是安全有效的治疗方 法,可以获得长期稳定的植活并不增加aGVHD和cGVHD等并发症。 展开更多
关键词 异基因干细胞移植 骨髓移植 联合移植 白血病
下载PDF
MHC半相合骨髓移植后慢性GVHD小鼠模型的建立 被引量:6
19
作者 邓兰 郭坤元 +2 位作者 尹晓林 李玉华 吴岚晓 《免疫学杂志》 CAS CSCD 北大核心 2005年第4期306-308,312,共4页
目的建立MHC半相合异基因骨髓移植(allo-BMT)后慢性GVHD小鼠模型。方法以(Balb/c×C57BL/6)F1H-2d/b(CB6F1)雌性小鼠为受者,预处理条件为不同剂量的全身照射(TBI,60Co照射),输注MHC半相合Balb/cH-2d雄性小鼠骨髓细胞与不同数量脾细... 目的建立MHC半相合异基因骨髓移植(allo-BMT)后慢性GVHD小鼠模型。方法以(Balb/c×C57BL/6)F1H-2d/b(CB6F1)雌性小鼠为受者,预处理条件为不同剂量的全身照射(TBI,60Co照射),输注MHC半相合Balb/cH-2d雄性小鼠骨髓细胞与不同数量脾细胞,观察移植后小鼠体质量变化,靶器官病理变化,血清抗ssDNA抗体、抗dsDNA抗体。结果在照射剂量为8Gy,输注骨髓细胞数量为8×106、脾细胞数量为4.5×107的小鼠至实验结束(移植后100d)全部存活,体质量减轻与对照组和其它实验组相比差异显著(P<0.05)。血清抗ssDNA抗体、抗dsDNA抗体较对照组和其它实验组显著升高(P<0.05)。该组皮肤、肝脏等病理改变明显。结论在照射剂量为8Gy,输注骨髓细胞数量为8×106、脾细胞数量为4.5×107的小鼠成功诱导出半相合allo-BMT慢性GVHD,为进一步研究慢性GVHD的发病机理、生物学特性、干预因素等打下了重要基础。 展开更多
关键词 骨髓移植 异基因 慢性移植物抗宿主病 小鼠
下载PDF
同种异体骨复合自体骨髓干细胞移植治疗良性骨肿瘤和瘤样病变 被引量:9
20
作者 刘英飞 王涛 张平德 《中国组织工程研究》 CAS CSCD 2013年第31期5652-5658,共7页
背景:同种异体骨是临床常用的骨移植材料,但缺乏诱导成骨能力是最大的问题。目的:评价良性骨肿瘤及瘤样病变刮除或切除后应用同种异体骨复合自体骨髓干细胞修复骨缺损的效果。方法:65例良性骨肿瘤(包括瘤样病变)患者,根据植骨情况分为2... 背景:同种异体骨是临床常用的骨移植材料,但缺乏诱导成骨能力是最大的问题。目的:评价良性骨肿瘤及瘤样病变刮除或切除后应用同种异体骨复合自体骨髓干细胞修复骨缺损的效果。方法:65例良性骨肿瘤(包括瘤样病变)患者,根据植骨情况分为2组。复合骨髓干细胞植骨组35例患者根据预计植骨量从每位患者两侧的髂前上棘或髂后上棘抽取红骨髓20-40mL,经体外分离、纯化、培养扩增骨髓基质干细胞备用,在植骨前将同种异体骨颗粒与骨髓基质干细胞充分混匀。肿瘤刮除或切除后,将混匀的骨髓基质干细胞与同种异体骨颗粒,植入骨缺损区内。单纯植骨组将用生理盐水浸泡半小时的同种异体骨植入骨缺损区内。分别于治疗后1,3,6,12个月进行植骨区X射线检查,比较两组病例同种异体骨颗粒界限模糊、消失的时间,同时观察术后并发症发生情况。结果与结论:62例患者均获得12个月以上随访。复合骨髓干细胞植骨组移植骨界限模糊时间和消失时间均短于单纯植骨组(P<0.05)。复合骨髓干细胞植骨组1例出现排异反应,使用免疫抑制剂治疗2周后痊愈,两组病例均未出现感染。结果表明同种异体骨复合自体骨髓干细胞植骨能明显促进骨融合和骨缺损的愈合。 展开更多
关键词 器官移植 细胞移植 同种异体骨 骨髓干细胞 移植 良性骨肿瘤 瘤样病变 骨融合 骨缺损
下载PDF
上一页 1 2 9 下一页 到第
使用帮助 返回顶部